Christopher Hewitt

Head of UK & Ireland medical affairs. Line managing two direct reports. Part of UK leadership team. Accountable for country medical affairs strategic planning for 7 promoted products in three therapy areas – rare oncology, rare endocrinology and rare metabolic diseases. Managing operational budget of €300,000. I am the head of ABPI / IPHA code compliance and lead medical signatory. I also have oversight of UK regulatory affairs / MHRA submissions for 16 products. I am also the medical lead for market access activities with NICE / SMC and with the Clinical Priorities Advisory Group of NHSE.

Working as part of the UK CMR Leadership Team, I led the development of a roadmap for the creation of a new therapy area in medical affairs at Novo Nordisk in the UK. This included development of strategic and operational plans to bring together several established products and pipeline assets under a single therapy area. I also created a workforce re organisation plan, spanning head office and field-based employees, to meet the customer engagement needs of the new operational model. I supported launch planning activities for three pipeline products spanning approximately 7 different indications. The work included support for product core scientific narrative development, market research, HEOR / market access activities, and real-world evidence gap analysis. I also functioned as a nominated medical signatory for the company, helping them to develop new work instructions / SOPs during their period of suspension from ABPI.

I wrote and provided training on a number of ABPI / IPHA / EFPIA compliance standard operating procedures including Materials Review (MLR), Meetings, Events & Hospitality, Fair Market Value, Grants, Donations & Event Sponsorship, Social Media, Interactions with members of the public, Disclosure of Transfers of Value, Recall & Withdrawal of Materials and Contracted Services. I also assisted with the configuration of their Salesforce CRM system, designed their Veeva Vault PromoMats MLR workflow and audited their medicinal samples process.